> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pentwater Funds Hold 3.9 Million Lantheus Shares In A Passive 6% Position
- URL: https://www.bullished.co/pentwater-funds-hold-3-9-million-lantheus-shares-in-a-passive-6-position-d005ff8e/
- Published: 2026-11-16T22:24:18.000Z
- Updated: 2026-11-16T22:24:18.000Z
- Description: The adviser and Matthew Halbower jointly reported the same fund-held shares, with shared voting power over the position.
- Author: Matteo Parrino
- Tags: SEC Filings, LNTH, Industry: Healthcare

Pentwater Capital Management's advised funds held [3.9 million shares](https://www.sec.gov/Archives/edgar/data/0001425851/000091957426008136/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) of [Lantheus](https://www.bullished.co/tag/lnth/), which makes radioactive drugs used mainly to image and track disease, representing a passive 6% common-stock position. The investment adviser reported the holding as of September 30 in an SEC ownership filing Monday.

## One Holding, Shared Voting Power

Matthew Halbower jointly reported the same 3.9 million shares. He is the sole shareholder of MCH PWCM Holdings, the general partner of Pentwater Capital Management; the shares themselves belong directly to funds advised by Pentwater.

Pentwater and Halbower each reported [shared voting power](https://www.sec.gov/Archives/edgar/data/0001425851/000091957426008136/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) over the full position. The funds are entitled to dividends and proceeds when the shares are sold.

The reported 6% uses a denominator of 65,299,875 common shares outstanding as of September 1, drawn from Lantheus's annual proxy filing submitted September 8\. The reporting persons certified that the securities were bought and held in the normal course of business, without an aim or effect of changing or influencing company control.

## Prostate, Heart And Alzheimer's Imaging

Lantheus's business spans cancer imaging and diagnostic agents. Pylarify is used in PET scans for prostate cancer, Definity improves heart ultrasound images, and Neuraceq is a PET imaging agent for Alzheimer's disease.

The Massachusetts-based company sells mainly to U.S. hospitals, independent imaging centers and government facilities. Its other activities include imaging software, licensing, royalties, research partnerships and contract manufacturing.

Lantheus also presented [TAUKLARIFY study results](https://www.globenewswire.com/news-release/2026/11/16/3403601/0/en/lantheus-presents-data-from-two-pivotal-phase-3-studies-of-tauklarify-florquinitau-f-18-injection-pet-imaging-in-early-alzheimer-s-disease.html?ref=bullished.co) Monday involving the detection of Alzheimer's-related tau tangles in cognitively impaired adults. Its two late-stage studies evaluated 617 scans against a reference standard that accommodated images from people with early symptomatic disease.

All five independent readers in each study met the preset thresholds for identifying both the presence and absence of tau pathology, the company said. Christopher Rowe, Austin Health's director of molecular imaging research and the presenting author, said [reliable detection matters](https://www.globenewswire.com/news-release/2026/11/16/3403601/0/en/lantheus-presents-data-from-two-pivotal-phase-3-studies-of-tauklarify-florquinitau-f-18-injection-pet-imaging-in-early-alzheimer-s-disease.html?ref=bullished.co) particularly in earlier clinical stages because tau tangles are closely linked to cognitive decline and prognosis.

Lantheus's market value was $6.6 billion as of 5:18 p.m. ET Monday.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — Pentwater Capital Management LP re: Lantheus Holdings, Inc. (LNTH)](https://www.sec.gov/Archives/edgar/data/0001425851/000091957426008136/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Lantheus Presents Data from Two Pivotal Phase 3 Studies of](https://www.globenewswire.com/news-release/2026/11/16/3403601/0/en/lantheus-presents-data-from-two-pivotal-phase-3-studies-of-tauklarify-florquinitau-f-18-injection-pet-imaging-in-early-alzheimer-s-disease.html?ref=bullished.co) — globenewswire.com

### More on Lantheus Holdings

- [Lantheus To Sell Springfield Plant — PharmaLogic Will Make Its Newly Approved Treatment](https://www.bullished.co/lantheus-to-sell-springfield-plant-pharmalogic-will-make-its-newly-approved-treatment-70a2dc9b/)
- [Lantheus Sets Aside Its Annual Outlook As Curium Deal Awaits Antitrust Clearance](https://www.bullished.co/lantheus-sets-aside-its-annual-outlook-as-curium-deal-awaits-antitrust-clearance-dd5ebaca/)
- [Lantheus And Curium Each Get FTC Second Request, Extending Merger Review Past The Standard Waiting Period](https://www.bullished.co/lantheus-and-curium-each-get-ftc-second-request-extending-merger-review-past-the-standard-7d8fa942/)

[All Lantheus Holdings (LNTH) coverage →](https://www.bullished.co/tag/lnth/)